drugset / Trial / NCT04450173
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Phase 2
Active not recruiting
40 enrolled
University of California, Davis
Genentech, Inc. · collabNational Cancer Institute (NCI) · collabPharmacyclics LLC. · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in treating follicular lymphoma compared to each drug alone.
Timeline
- Start
- 2021-02-24
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |